PTGX Protagonist Therapeutics, Inc Insider Trading

Director William D. Waddill sells 9,000 PTGX shares at $117.94 under pre-arranged 10b5-1 plan; retains 7,825 shares.

Director William D. Waddill sold 9,000 shares at $117.94 on 2026-06-23 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-27, reducing his non-derivative holdings by 53.5% to 7,825 shares. The trade is scheduled rather than discretionary, so it reflects plan mechanics rather than a real-time market judgment. Protagonist Therapeutics has experienced severe turbulence: annual revenue declined 89.4% year-over-year and the company was unprofitable over its most recent full fiscal year, though the latest quarter showed $56.4M revenue and $3.8M net income. The stock has recovered 22.6% over the past 30 days and 23.9% over 90 days, trading at $122.63 (2.9% below its 52-week high of $126.25). Investors should monitor whether further 10b5-1 execution or additional open-market sales emerge, as well as the company's ability to sustain recent profitability amid the prior year's sharp revenue decline.

CEO Dinesh Patel exercised options and sold all 75,000 shares same-day for $7.5M, offsetting his stock position while stock trades near 52-week highs.

Dinesh Patel, the company's President and CEO, executed a textbook option exercise-and-sell on the same day: acquiring 75,000 shares through a stock option exercise and immediately liquidating the entire position. The combined transactions netted approximately $5.9M in proceeds after acquisition costs. This is the 19th open-market sale Patel has executed in the past three years, continuing a persistent selling pattern with no open-market purchases during that same window. His prior sales at this company show mixed timing: four of his five most recent exits at PTGX were poorly timed (the stock rose afterward), while one was well-timed (the stock fell). The current sale occurs while the stock trades near its 52-week high following a sharp rally over the prior three months, though the company's fundamentals remain stressed—it is unprofitable with significant revenue contraction. The exercise-and-sell structure is routine for options management, but the consistent avoidance of open-market purchases and the heavily tilted selling track record warrant noting.

Director Bryan Giraudo sells nearly $6M in PTGX stock while simultaneously exercising $238K in options—mixed signal from a board member with a strong buy-timing track record.

Director Bryan Giraudo exercised options to acquire 36,000 shares but then immediately sold 59,130 shares over two days, netting a disposition of roughly 23,000 shares worth nearly $6M. This two-sided transaction is contradictory: the option exercise suggests some conviction in the company's direction, yet the rapid and much larger sale signals a reduction in his equity exposure. Giraudo's prior trades show a strong history of well-timed purchases, with prior buys consistently delivering positive returns—yet this filing reverses that pattern by shifting to net seller status. The company's fundamentals are challenged, showing significant revenue contraction and a net loss, which provides some rationale for liquidating shares. Giraudo's placement of large sales on the open market after exercising newly-vested options suggests he may be executing a planned divestiture rather than responding to immediate price movement, especially given that the stock is trading only slightly below its 52-week high.

PTGX CMO Arturo Molina sold 15,000 shares at $104.79 on 2026-03-26 (~$1.6M), retaining 84.1K shares.

Molina sold 15,000 shares at $104.79, near the 52-week high of $104.31, while retaining substantial holdings of 84.1K shares post-transaction. His cross-ticker track record shows a 90d well-timed rate of 83.33% across 10 prior sells, suggesting consistent skill in exit timing. However, his PTGX-specific history presents a contrasting picture: prior sales on 2026-01-27, 2026-01-26, 2026-01-23, and 2026-01-20 all saw positive 30-day returns (+7.8%, +5.9%, +0.4%, +0.7% respectively), indicating those exits preceded gains rather than declines; only 1 of 1 measurable PTGX sales achieved well-timed outcomes at the 90-day mark. The company's fundamentals remain challenged with annual revenue growth of -89.4%, $-39.3M net income, and $4.7M latest quarterly revenue, despite a $6.3B market cap. This sale pattern—repeated exits near highs combined with deteriorating fundamentals—merits scrutiny given the divergence between cross-ticker timing acumen and PTGX-specific execution outcomes.

Director Selick sells 24,000 PTGX shares at $105.00; stock down to $98.97, company burning $39.3M annually on $4.7M quarterly revenue.

Director Harold E Selick sold 24,000 shares (28.3% of his pre-transaction holdings) at $105.00 on 2026-03-26, executing at a price currently above the $98.97 market level but 5.1% below the 52-week high. The sale occurred in a company facing severe financial stress: annual revenue growth was -89.4%, net income was negative $39,339,000.00 in the most recent full fiscal year, and the latest quarter shows only $4,712,000.00 in revenue against continued operating losses. The director retained 60,845 shares post-transaction, maintaining a meaningful stake in the business. This sale represents a discrete reduction in an insider's position at a relatively elevated price point in the context of the company's deteriorating financial trajectory and depressed annual growth profile.

CFO Ali Asif sold 24.8K PTGX shares at $104.24 for $2.6M, reducing stake 29.0%; stock now -5.1% from 52-week high.

Ali Asif, Chief Financial Officer, executed a substantial sale of 24,765 shares (reducing his holding from 85,518 to 60,753 shares, a -29.0% reduction) at $104.24 on 2026-03-26 for a total value of $2,581,503.60. The current price of $98.97 is now -5.1% from the 52-week high of $104.31, and the stock is within 5% of where the CFO sold it. Looking at his same-ticker history at PTGX, his prior 90-day measurable outcome (sell on 2025-03-12) showed a -4.0% 90-day return—a pattern consistent with selling before declines. His cross-ticker track record shows a 100.00% well-timed rate on prior sells with an average 90-day return of -9.2%, indicating a consistent pattern of exiting before downturns across all holdings. Against a backdrop of severe fundamentals (annual revenue growth of -89.4%, latest-quarter revenue of $4.7M, net income of $-39.3M), the CFO's sale of nearly 30% of his stake warrants close monitoring of future quarterly results and operational developments.

CEO Patel sold 54,700 shares at $101.00 across 2 transactions ($5.5M) as stock nears 52-week high of $104.31.

Dinesh V Patel, President and CEO, executed 2 separate sales totaling 54,700 shares for $5,524,700.00 on March 24–25, 2026, reducing his holdings by 9.4% from 579,638 to 524,938 shares. The transactions occurred at $101.00 per share while the stock currently trades at $104.31, near its 52-week high of $104.31, in the context of a 30-day gain of +20.5% and 90-day gain of +17.4%. At PTGX specifically, Patel's 5 prior sales show inconsistent outcomes: 3 posted 30-day gains ranging +0.7% to +6.2%, while 1 posted a 30-day loss of -2.2%, with no 90-day outcomes yet measurable. The underlying company reported quarterly revenue of $4,712,000.00 with a net loss of $-39,339,000.00, annual revenue contraction of -89.4%, and an unprofitable fiscal year, alongside a market cap of $6,655,887,165.96. The CEO's sale comes at elevated valuation (stock at 52-week high) within a fundamentally challenged context (deep losses, revenue collapse).

Director Williams Lewis T sold 18,000 shares of PTGX at $82.42; holdings reduced 69.7% to 7,825 shares

Director Williams Lewis T executed a material reduction in his PTGX position, selling 18,000 shares (69.7% of his pre-transaction holdings) at $82.42 on 2026-02-17 for a total value of $1,483,560.00. The company is currently unprofitable with a net income of $-39,339,000.00 against quarterly revenue of $4,712,000.00, though it has achieved explosive 624.1% annual revenue growth. At a market cap of $5,188,175,121.34 and P/E of 113.68, the stock is priced at a substantial premium to traditional valuation metrics, and is currently 13.0% below its 52-week high of $95.35. The director's substantial stake reduction leaves only 7,825 shares post-transaction, warranting attention to whether this reflects a structural reassessment of the company's value proposition or capital allocation priorities.

Director William D. Waddill sold 20,000 shares of PTGX at $83.68, reducing position by 71.9% to 7,825 shares

Director William D. Waddill sold 20,000 shares (20.0K shares) at $83.68 on 2026-02-06, liquidating 71.9% of his holdings and leaving a post-transaction position of 7,825 shares (7.8K shares). The company trades at a P/E of 115.74 with a market cap of $5,281,948,620.34 ($5.3B), while reporting quarterly revenue of $4,712,000.00 ($4.7M) against net income of $-39,339,000.00 ($-39.3M). The substantial reduction in Waddill's stake—divesting nearly three-quarters of his holdings—warrants examination of the company's profitability trajectory and whether the director's decision reflects structural concerns at a firm with outsized valuation relative to current earnings generation.

CMO Molina sells 23,151 shares at $82.30 avg; holds 84,115 shares post-sale, paring stake by 21.6%

Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, executed 3 separate sales totaling 23,151 shares for $1,905,305.42 across three trading days (2026-01-23 to 2026-01-27), reducing his holdings by 21.6% from 107.3K to 84.1K shares. His same-ticker history shows mixed outcomes: 3 of 4 prior measurable sales at PTGX were well-timed at the 90-day mark, suggesting tactical execution consistency. The current stock price of $83.08 is only 0.78 above the blended sale average of $82.30, indicating the sales occurred near recent market levels. The company shows high-growth fundamentals (+624.1% annual revenue growth) but significant losses (-$39.3M net income on $4.7M quarterly revenue) and an elevated valuation (P/E 113.81), creating tension between growth narrative and profitability metrics. The sale magnitude and timing warrant monitoring of whether this reflects systematic rebalancing or a shift in executive positioning relative to near-term company prospects.